Simulations Plus, Inc.
1220 West Avenue J
Tel: 888-266-9294 US and Canada 661-723-7723<br>
318 articles with Simulations Plus, Inc.
Simulations Plus, Inc. announced that its board of directors has declared its next ongoing quarterly cash dividend of $0.06 per share of the Company’s common stock.
Jill Fiedler-Kelly named President along with other promotions and key additions
New intra-articular injection route will expand the suite of drug delivery options available in GastroPlus®
Center for Veterinary Medicine to apply GastroPlus® to assess product bioequivalence in canines
Simulations Plus, Inc. (Nasdaq: SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today reported financial results for its third quarter of fiscal year 2019 (3QFY19) and the first nine months of fiscal year 2019 (9moFY19), the period ended May 31, 2019.
Enhancements include improved data handling and command line functionality
Conference Call to be on Wednesday, July 10, 2019, at 4:15 PM ET
Substantial update of NAFLD drug efficacy software offers a broad range of pathophysiology and over a thousand simulated patients for testing
User- and collaboration-driven functionality in version 9.7 expands the science of local and systemic exposure
Japanese government organization to train reviewers to efficiently analyze PBPK model submissions
U.S. FDA Remains Committed to Streamline & Accelerate Drug Development using Model-Informed Drug Development (MIDD) technology
Simulations Plus, Inc. announced that Shawn O’Connor, chief executive officer, will present at the 20th Annual B. Riley FBR Institutional Investor Conference on Wednesday, May 22, at 10:30 a.m. (PDT) in Room 8.
Simulations Plus, Inc. (Nasdaq:SLP), the premier provider of simulation and modeling software and consulting services for all stages of pharmaceutical discovery and development, today announced the appointment of Dr. Lisa LaVange to the Company’s Board of Directors.
Simulations Plus, Inc. (Nasdaq:SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that it has received an order from the U.S. Food and Drug Administration (FDA) for a 15-user license to its ADMET Predictor® software suite.
New machine learning models and novel analysis methods address customer requests
Simulations Plus, Inc. (Nasdaq:SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today reported financial results for its second quarter of fiscal year 2019, the period ended February 28, 2019 (2QFY19).
Conference Call to be on Tuesday, April 9, 2019, at 4:15 PM ET
Phase II Award of NIH Fast Track SBIR Grant for Drug-induced Kidney Injury Software, RENAsym™, Funds Development Over Next 20 Months
New models for in vitro systems lead to improved inputs for GastroPlus® simulations
Mr. O’Connor will host one-on-one meetings throughout the day at the conference which will be held at the Lotte New York Palace Hotel.